Fabry Disease, also known as Anderson-Fabry Disease, is closely related to mucopolysaccharidoses and is one of a number of disorders known as lysosomal storage diseases.
Children and adults with Fabry are missing, or are deficient in an enzyme called alpha-galactosidase A which is essential in breaking down certain waste products in the lysosomes of many different types of cell.
The main waste product is ceramide rihexosidase (CTH), also known as globotriaosylceramide, Gb3 or Gl3.
When these waste products are not completely broken down they build up within the cells of the body causing progressive damage. Babies may show little sign of the disease but as more and more cells become damaged by an accumulation of these waste products, symptoms start to appear.
Fabry encompasses a wide spectrum of clinical symptoms which may or may not appear in all individuals with this disease. This, together with the rarity of the disease, often delays diagnosis.
Many individuals may experience some of the symptoms that are outlined here before receiving an actual diagnosis of Fabry.
MPS Commercial have produced a series of publications on behalf of the Fabry International Network which present the findings from research carried out in the Fabry community. You can download the first issue releases in summer 2019.
Our helpline is open 9-5pm
Monday-Friday: 0345 389 9901
Out of hours support line open 5pm-10pm Monday-Friday and weekends:
07712 653 258
For available treatment options and the latest news and information on research, therapies and clinical trials please visit our treatment section.